07:15 AM EDT, 04/09/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We adjust our target price to $44 from $47, implying a 2025 P/E of 19.1x, largely in line with peer average. This is slightly lower than its historical forward P/E average of 21x-22x, reflecting current market uncertainty. Qiagen ( QGEN ) raised its 2025 adjusted EPS guidance after posting a rather strong preliminary Q1 2025 results, where both preliminary net sales and adjusted EPS came in above the previously communicated outlook. We forecast sales to grow 3% in 2025, with the Diagnostic Solutions segment being the main driver, and operating income margin to improve to around 30%, at the lower end of Qiagen's ( QGEN ) guidance of "above 30%". We keep our 2025 EPS estimate of $2.30, which comes in slightly below the upgraded guidance of $2.35 at CER (previously $2.28 at CER, with an estimated negative currency impact of $0.02-$0.03). We are encouraged to see Qiagen's ( QGEN ) strong start to the year but remain mindful that ongoing geopolitical uncertainty could affect near-term sentiment for both the stock and the sector as a whole.